BRPI0409562A - tratamento de condições envolvendo placas amilóides - Google Patents

tratamento de condições envolvendo placas amilóides

Info

Publication number
BRPI0409562A
BRPI0409562A BRPI0409562-6A BRPI0409562A BRPI0409562A BR PI0409562 A BRPI0409562 A BR PI0409562A BR PI0409562 A BRPI0409562 A BR PI0409562A BR PI0409562 A BRPI0409562 A BR PI0409562A
Authority
BR
Brazil
Prior art keywords
treatment
conditions involving
amyloid plaques
involving amyloid
administering
Prior art date
Application number
BRPI0409562-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Stephen M Strittmatter
Daniel H S Lee
Weiwei Li
Original Assignee
Univ Yale
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale, Biogen Idec Inc filed Critical Univ Yale
Publication of BRPI0409562A publication Critical patent/BRPI0409562A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0409562-6A 2003-04-16 2004-04-16 tratamento de condições envolvendo placas amilóides BRPI0409562A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46342403P 2003-04-16 2003-04-16
PCT/US2004/011728 WO2004093893A2 (en) 2003-04-16 2004-04-16 Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques

Publications (1)

Publication Number Publication Date
BRPI0409562A true BRPI0409562A (pt) 2006-04-18

Family

ID=33310776

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409562-6A BRPI0409562A (pt) 2003-04-16 2004-04-16 tratamento de condições envolvendo placas amilóides

Country Status (15)

Country Link
US (1) US20070065429A1 (https=)
EP (1) EP1615654A2 (https=)
JP (1) JP2006523708A (https=)
KR (1) KR20060023959A (https=)
CN (1) CN1832752A (https=)
AU (1) AU2004231742A1 (https=)
BR (1) BRPI0409562A (https=)
CA (1) CA2522649A1 (https=)
EA (1) EA009643B1 (https=)
IS (1) IS8081A (https=)
MX (1) MXPA05011100A (https=)
NO (1) NO20055392L (https=)
RS (1) RS20050774A (https=)
WO (1) WO2004093893A2 (https=)
ZA (1) ZA200509242B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
PT1534736E (pt) * 2002-08-10 2010-09-07 Univ Yale Antagonistas do receptor nogo
US20080274112A1 (en) * 2003-08-07 2008-11-06 Lee Daniel H S Nogo Receptor Antagonists
CA2549956C (en) * 2003-12-22 2016-04-12 Glaxo Group Limited Immunoglobulins
CA2555018A1 (en) * 2004-01-30 2005-08-18 Biogen Idec Ma Inc. Treatment of conditions involving dopaminergic neuronal degeneration using nogo receptor antagonists
US8269141B2 (en) 2004-07-13 2012-09-18 Lincoln Global, Inc. Power source for electric arc welding
US9956639B2 (en) 2005-02-07 2018-05-01 Lincoln Global, Inc Modular power source for electric ARC welding and output chopper
US9855620B2 (en) 2005-02-07 2018-01-02 Lincoln Global, Inc. Welding system and method of welding
US9647555B2 (en) 2005-04-08 2017-05-09 Lincoln Global, Inc. Chopper output stage for arc welder power source
CA2913655A1 (en) 2006-01-27 2007-08-09 Biogen Ma Inc. Nogo receptor antagonists
EP2081429A4 (en) * 2006-08-31 2010-01-06 Biogen Idec Inc PROCESS FOR PERIPHERAL ADMINISTRATION OF NOGO RECEPTOR POLYPEPTIDES
EP2276500A4 (en) 2008-03-13 2015-03-04 Univ Yale REACTIVATION OF AXON GROWTH AND AXON RECOVERY IN CHRONIC REVERSE MARKET INJURIES

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) * 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) * 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) * 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) * 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) * 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4366241A (en) * 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4510245A (en) * 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) * 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
WO1999066041A1 (en) * 1998-06-16 1999-12-23 Human Genome Sciences, Inc. 94 human secreted proteins
US6391311B1 (en) * 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
IL150566A0 (en) * 2000-01-12 2003-02-12 Univ Yale Nucleic acids and polypeptides and nogo-receptor proteins
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
NZ525422A (en) * 2000-10-06 2006-09-29 Biogen Idec Inc Isolated polynucleotides comprising a nucleic acid which encodes a polypeptide which modulates axonal growth in CNS neurons
JP2005507246A (ja) * 2001-08-27 2005-03-17 ノバルティス アクチエンゲゼルシャフト Ｎｏｇｏレセプターホモログおよびそれらの使用
WO2003035687A1 (en) * 2001-10-22 2003-05-01 Novartis Ag Nogo receptor homologues and their use
PT1534736E (pt) * 2002-08-10 2010-09-07 Univ Yale Antagonistas do receptor nogo
US20080274112A1 (en) * 2003-08-07 2008-11-06 Lee Daniel H S Nogo Receptor Antagonists

Also Published As

Publication number Publication date
WO2004093893A2 (en) 2004-11-04
IS8081A (is) 2005-10-21
CA2522649A1 (en) 2004-11-04
KR20060023959A (ko) 2006-03-15
JP2006523708A (ja) 2006-10-19
AU2004231742A2 (en) 2004-11-04
EA200501620A1 (ru) 2006-06-30
RS20050774A (sr) 2007-12-31
NO20055392L (no) 2005-11-15
EA009643B1 (ru) 2008-02-28
US20070065429A1 (en) 2007-03-22
CN1832752A (zh) 2006-09-13
MXPA05011100A (es) 2006-04-18
ZA200509242B (en) 2006-12-27
AU2004231742A1 (en) 2004-11-04
EP1615654A2 (en) 2006-01-18
WO2004093893A3 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
CL2008001960A1 (es) Compuestos derivados de tetrahidropiranocromano, procedimiento de preparacion, composicion farmaceutica, util para inhibir gamma-secretasa, destinados al tratamiento de enfermedades neurodegenetarivas, enfermedad de alzheimer e inhibir el deposito de proteina amiloide.
EA200501891A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
EA200602015A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
DK1608350T3 (da) Fremgangsm der til forebyggelse, behandling og diagnosticering af lidelser af proteinaggregation
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
UY29284A1 (es) Anticuerpos ab(beta) humanizados usados en mejorar la cognicion
DK1613347T3 (da) Humaniserede antistoffer, der genkender beta-amyloidpeptid
NO20092051L (no) Fremgangsmater og kombinasjonsterapier for behandling av Alzheimers sykdom
BRPI0409562A (pt) tratamento de condições envolvendo placas amilóides
BRPI0812504B8 (pt) composto para profilaxia ou tratamento de doença ou condição associada a receptor de canabinoides em sujeito mamífero
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
EP1463531A4 (en) PROCESS FOR INHIBITING OKULAR PROCESSES
BRPI0519124A2 (pt) composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço
EA200600071A1 (ru) Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
DK1670903T3 (da) Behandling af neurodegenerative sygdomme
ATE496892T1 (de) Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
MXPA05013151A (es) 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b.
DK1786442T3 (da) Behandling af neurodegenerative sygdomme under anvendelse af DEGS-inhibitorer
BR0315462A (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação
DK1553985T3 (da) Biphenyler som billeddannelsesmiddel i forbindelse med Alzheimers sygdom
BR0314540A (pt) Métodos para o tratamento de neurodegeneração
WO2005108599A3 (en) Compositions and methods for treatment of protein misfolding diseases
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.